Compare Essex Property Trust, Inc. (ESS) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Novavax Inc — how do they compare? Essex Property Trust, Inc. trades at $282.11 (market cap $18.20B), while Novavax Inc trades at $7.95 (market cap $1.30B). The key difference: Essex Property Trust, Inc. is far larger — about 14× Novavax Inc's market cap, and Essex Property Trust, Inc. pays a 3.66% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| ESS | NVAX | |
|---|---|---|
Market Cap | $18.20B | $1.30B |
Sector | Real Estate | Health |
52-Week High | $298.33 | $11.19 |
52-Week Low | $239.61 | $6.22 |
Enterprise Value | $24.80B | $879.40M |
Dividend Yield | 3.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $288.1, up 1.05% daily, with a neutral technical signal and support near $284. The stock shows strong profitability with a 21.48% net margin and recent Q2 2026 earnings miss on EPS but beat on FFO, leading to raised full-year guidance. Revenue growth is steady, reaching $1.89B in 2025, though net income declined to $670M from $742M in 2024.
Outlook is cautiously optimistic with a consensus price target of $305.86, implying ~6% upside. Risks include high debt levels (debt-to-asset ratio of 51.92% in 2024) and regional economic exposure. Analyst sentiment is mixed with 40% buy ratings, but institutional interest grew with Amundi increasing its stake in Q1 2026.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
